Tarsons Products Reports Q4 FY26 Results

Consolidated Revenue (Q4 FY26): ₹121 crore
Consolidated Revenue (FY26): ₹426 crore

Reader Takeaway: Domestic growth is a positive, but margin pressure and export headwinds pose challenges.

What just happened

Tarsons Products Limited announced its financial results for the quarter and financial year ended March 31, 2026. Consolidated revenue for the fourth quarter (Q4 FY26) stood at ₹121 crore, and for the full financial year (FY26) it was ₹426 crore. On a standalone basis, revenue from operations in Q4 FY26 increased by approximately 4.3% year-on-year to ₹97 crore.

Why this matters

The results highlight a mixed performance. The company's domestic business showed strong momentum, growing 11.7% year-on-year in Q4 FY26, indicating healthy demand in its home market. However, the export business faced significant headwinds, declining by 13.4% in the same quarter, attributed to geopolitical tensions and supply chain issues.

Profitability metrics reveal challenges. Gross margins were negatively impacted by raw material price volatility in February and March. Furthermore, EBITDA margins were affected by increased operating expenses linked to new plant facilities. Management indicated a cautious approach to pricing, gradually increasing prices to avoid losing market share to competitors.

The backstory

Tarsons Products has been undergoing a significant investment phase, with heavy capital expenditure largely behind it. The company reported total depreciation of ₹87 crore for FY26.

What changes now

With the major capital expenditure phase nearing completion, Tarsons Products is shifting focus towards operational ramp-up and improving cash generation. The company expects standalone depreciation to be between ₹105 crore and ₹110 crore in FY27. Maintenance capital expenditure for FY27 is estimated at around ₹20 crore.

Risks to watch

Key concerns include the continued impact of geopolitical tensions on export revenues, ongoing pressure on margins due to raw material price volatility which is expected to affect Q1 FY27 results, and limited pricing power in a competitive market.

Peer comparison

While specific peer comparison data is not provided in the filing, the company's management mentioned competition from Multi-National Corporations (MNCs) and other players in the market, highlighting the challenges in passing on cost increases.

Context metrics (time-bound)

Consolidated Cash PAT for FY26 grew by approximately 21.7% to ₹112 crore, up from ₹92 crore in FY25.

What to track next

Investors will be watching the company's ability to manage raw material costs, improve export performance, and scale up new product categories like bioprocess and cell culture. The focus on gradual price adjustments and debt reduction will also be crucial.